Financial Analysis: Fulcrum Therapeutics (NASDAQ:FULC) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)

Fulcrum Therapeutics (NASDAQ:FULC) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Fulcrum Therapeutics and Lakefront Biotherapeutics American Depositary Shares, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4	7	1	0	1.75
Lakefront Biotherapeutics American Depositary Shares	0	7	1	1	2.33

Fulcrum Therapeutics presently has a consensus target price of $8.20, suggesting a potential upside of 114.66%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $30.67, suggesting a potential upside of 10.99%. Given Fulcrum Therapeutics’ higher probable upside, research analysts clearly believe Fulcrum Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Profitability

This table compares Fulcrum Therapeutics and Lakefront Biotherapeutics American Depositary Shares’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-25.38%	-24.15%
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A

Institutional and Insider Ownership

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Fulcrum Therapeutics and Lakefront Biotherapeutics American Depositary Shares”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	N/A	N/A	-$74.88 million	($1.21)	-3.16
Lakefront Biotherapeutics American Depositary Shares	$1.26 billion	1.45	$363.05 million	($1.41)	-19.60

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Fulcrum Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Fulcrum Therapeutics has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.